What the FDA Approval List Actually Tells You About a Surgical Robot
510(k) clearance is a safety threshold, not a performance endorsement. Here's how to read the regulatory record the way a procurement team should.
In the spring of 2024, Intuitive Surgical received FDA 510(k) clearance for the da Vinci 5, its fifth-generation multiport system. The press release used the word "clearance." The same week, trade coverage used the word "approval." Vendor sales decks, predictably, used "FDA-approved" for systems that had actually received clearance — a different regulatory category with a meaningfully different evidentiary standard.
If your OR director, surgical chair, or CFO does not understand the difference, they are reading every vendor's regulatory claim through the wrong lens.
This article explains the three pathways a surgical robot can travel to reach the U.S. market, what each one actually requires, how to look up any system's regulatory history in the FDA's public database, and why the clearance itself is only the beginning of the question a procurement team should be asking.
The Three Pathways — and What Each One Proves
510(k) Clearance: "Substantially Equivalent"
The vast majority of surgical robot platforms that reach the U.S. market do so via 510(k). This pathway does not require the manufacturer to demonstrate clinical superiority, or even clinical equivalence in outcomes, to an existing standard of care. It requires the manufacturer to demonstrate "substantial equivalence" to a legally marketed predicate device — meaning similar intended use and similar technological characteristics.
The FDA reviews the submission and either clears the device (not "approves" it) or issues a not-substantially-equivalent finding. The typical review clock runs 90 days, though complex submissions take longer.
What 510(k) clearance tells you: the FDA has determined that the device's safety and effectiveness profile is substantially equivalent to a device already on the market. It does not tell you the system produces better outcomes than open surgery, better outcomes than laparoscopy, or better outcomes than a competing robotic platform.
Recent 510(k) clearances relevant to procurement:
- da Vinci 5 (Intuitive Surgical) — cleared March 2024 for multiport robotic-assisted minimally invasive surgery
- Versius (CMR Surgical) — cleared October 2024 for cholecystectomy; Versius Plus cleared December 2025 for expanded indications
- Hugo RAS (Medtronic) — cleared December 2025 for urologic procedures
PMA: Premarket Approval
Premarket Approval is the most stringent FDA pathway, required for Class III devices — those that support or sustain human life or present significant risk. PMA requires clinical data demonstrating the device is safe and effective for its intended use. A randomized controlled trial is typically required.
Most surgical robotic systems have not sought PMA because they cleared the lower 510(k) bar by referencing an older robotic predicate. This is legal and standard practice. It means, however, that the FDA clearance letter is not itself evidence of superiority over alternative approaches.
De Novo: First-of-a-Kind Without a Predicate
When a device is novel and no appropriate predicate exists, manufacturers can seek De Novo classification. This pathway allows the FDA to create a new device classification and establish special controls. Devices cleared via De Novo then serve as predicates for future 510(k) submissions. Some early robotic surgery systems traversed this path.
How to Use the FDA Database Yourself
The FDA's 510(k) database is publicly searchable at accessdata.fda.gov. Any OR director or procurement lead can search by company name or device name in under five minutes.
What to look for:
Decision date — When was the system cleared? A system cleared in 2014 for a specific indication and then expanded via subsequent clearances may have a patchwork of approved uses that don't match the vendor's current marketing language.
Indications for use — This is the exact language FDA has cleared. If a vendor's sales team says their robot is cleared for a procedure you care about, verify the indication language yourself. "Minimally invasive surgery" is broad; "robotic-assisted laparoscopic radical prostatectomy" is specific. They are not interchangeable.
Predicate devices — The 510(k) summary will identify what predicate the manufacturer cited. For newer entrants, the predicate is frequently the da Vinci Si or da Vinci Xi. This creates a lineage: if the predicate has any known safety issues or limitations, those are the baseline the new system is being compared against.
Special controls and conditions — Some clearances include conditions. Read them. Surgeon training requirements, proctoring minimums, and case-volume thresholds sometimes appear as conditions of clearance.
What the FDA Record Cannot Tell You
Clearance is a market-entry decision, not an outcomes endorsement. Understanding these limitations is essential for procurement:
Clinical outcomes are not in the clearance record. The FDA's 510(k) review does not require the manufacturer to prove the device produces better surgical outcomes, shorter recovery times, lower complication rates, or lower readmission rates. These questions are answered — to the extent they're answered at all — by peer-reviewed clinical literature, not by the FDA letter.
Clearance for one procedure does not imply equivalence for another. A system cleared for cholecystectomy (gallbladder removal) is not by that fact cleared for colorectal resection, gynecologic surgery, or urologic procedures. Vendors have distinct clearances for distinct procedure types, and the breadth of cleared indications varies considerably across platforms. As of early 2026, Hugo's U.S. clearance is limited to urology; CMR Versius's U.S. clearance covers cholecystectomy. Intuitive da Vinci Xi and SP have broader indication coverage accumulated over many years and subsequent 510(k) submissions.
Cleared does not mean reimbursed. CMS and commercial payors make separate coverage decisions. A procedure performed robotically may or may not receive a distinct reimbursement code from the same procedure performed laparoscopically. In most cases in the U.S., robotic-assisted surgery does not carry a separate CPT code — the facility absorbs the equipment cost difference within the same DRG or facility fee. This is a capital and operating cost issue your finance team should model explicitly.
Cleared does not mean privileged. Hospital credentialing is separate from FDA clearance. Surgeon privileges for robotic procedures are granted by your institution's credentialing committee under its own standard. A surgeon cleared to operate a da Vinci Xi at another institution must typically complete your institution's credentialing process separately.
Reading Vendor Claims Against the Regulatory Record
Here is a short checklist for evaluating any vendor's regulatory language in a sales context:
| Vendor claim | What to verify |
|---|---|
| "FDA-approved" | Is it cleared (510k) or approved (PMA)? These are different. Most platforms are cleared. |
| "Cleared for [procedure]" | Pull the 510(k) indication language. Does it match your actual use case? |
| "First robotic system to receive FDA clearance for X" | Check the De Novo and 510(k) databases. "First" claims are frequently imprecise. |
| "The most widely cleared robotic platform" | Count clearance numbers across the platform's full lifecycle, not just the current model. Intuitive has decades of successive submissions; newer entrants cannot match this — which is not a safety disqualification but is context. |
| "Cleared internationally" — CE Mark, PMDA, NMPA | These are separate regulatory bodies with different standards. CE Mark in Europe under MDR is not equivalent to FDA clearance and vice versa. |
The Expanded Competitive Landscape as of 2026
The surgical robotics regulatory map has changed meaningfully since 2022:
Intuitive Surgical (da Vinci Xi, X, SP, and now da Vinci 5) has the longest U.S. clearance history and the broadest cleared indication library. This is a genuine procurement advantage: surgeons across your service line are more likely to find cleared indications for their procedures on the Intuitive platform than on a newer entrant.
CMR Surgical (Versius, Versius Plus) received initial U.S. cholecystectomy clearance in 2024. Versius Plus followed in 2025. The system has wider European deployment. Its modular design — separate arm units rather than one patient cart — is a material handling difference that affects OR setup, room configuration, and storage. The indication library in the U.S. remains limited relative to Intuitive as of early 2026.
Medtronic (Hugo RAS) received U.S. clearance for urology in late 2025, following CE Mark in Europe where it has more procedure experience. Hugo's modular arm architecture is similar in concept to Versius. Its U.S. market entry is early-stage; expect indication expansion filings in 2026.
Stryker (Mako SmartRobotics) — orthopedics only. Cleared for total knee, total hip, and unicompartmental knee arthroplasty. The regulatory and clinical evidence base for Mako is specific to orthopedic surgery; it is not a soft-tissue platform and should not be compared to da Vinci or Hugo in the same RFP.
Asensus Surgical (Senhance) — holds FDA clearance for multiple laparoscopic procedures and has a haptic feedback capability that distinguishes it technically. Market presence is smaller than Intuitive or the new Medtronic/CMR entrants.
Globus Medical (ExcelsiusGPS) — spine surgery only; cleared for robot-assisted pedicle screw placement. Competes with Zimmer Biomet's ROSA Spine.
Smith & Nephew (CORI) — orthopedic; cleared for partial and total knee arthroplasty. Competes with Mako in orthopedic procurement.
The One Question the FDA Record Answers Best
After all this, the FDA record has a narrow but important function in procurement: it tells you whether a system can legally be used for a specific procedure in the U.S., and under what conditions.
That is a necessary but not sufficient screening criterion. A system that lacks clearance for your target procedure is disqualified immediately. A system that has clearance has passed the minimum threshold — not the full evaluation.
The next questions — outcomes evidence, surgeon adoption, per-procedure economics, support coverage, and lifecycle commitments — are the ones that determine value. Those are the subjects of the remaining articles in this series.
Next in this series: Surgical Robot TCO: Capital, Consumables, Training, and Per-Procedure Cost
